National and Kapodistrian University of Athens
Mελέτη μεταγευματικής λιπαιμίας σε άτομα με σακχαρώδη διαβήτη τύπου 2: σύγκριση θεραπείας με λιραγλουτίδη έναντι εξενατίδης
Abstract
dc:descriptionGlucagon like peptide-1 (GLP-1) is a gut incretin hormone secreted in response to nutrient ingestion. It has several physiological effects mediated by the widely expressed GLP-1 receptor. Following binding to and activation of the GLP-1 receptor in pancreatic β cells, insulin secretion is elicited in a glucose dependent manner. The effects of GLP-1 are impaired in patients with type 2 diabetes mellitus (T2DM).Therapeutic approaches based on the actions of the incretin hormone GLP-1 have been widely established in the management of T2DM.Nevertheless, less research has been aimed at elucidating the role of GLP-1 on lipid metabolism and in particular postprandial dyslipidaemia. Exenatide and liraglutide are two GLP-1 receptor agonists which are currently available as subcutaneously administered treatment for T2DM but their chronic effects on postprandial lipaemia have not been well investigated.The aim of this study was to compare the effect of treatment with either liraglutide or exenatide for two weeks on postprandial lipaemia in obese subjects with T2DM. Although exenatide and liraglutide share the same basic mechanisms of action, differences in pharmacokinetic and pharmacodynamic characteristics, such as differences in gastric emptying, translate into differential effects on parameters of fasting and postprandial glycaemia and presumably of postprandial lipaemia.This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 obese subjects with T2DM. Patients were randomized to receive either liraglutide or exenatide treatment and underwent a standardized meal tolerance test early in the morning after a 10-h fast at baseline (visit 1– beginning of treatment) and after a two week treatment period (visit 2). At each of the two visits the following parameters were recorded for each patient: serum cholesterol, high density lipoproteins (HDL), low density lipoproteins (LDL), triglycerides, insulin and glucose. Each parameter was measured at 0 (fasting), 120 and 240 minutes after the ingestion of the lipid meal. The present study is the first to compare the effects of exenatide and liraglutide on postprandial lipaemia in obese patients with T2DM. Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two week treatment. The mechanisms which lead to this phenomenon, which seem to be independent of gastric emptying, are yet to be studied.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Voukali, Maria
- Βούκαλη, Μαρία
Subjects
dc:subject × 22- Ινκρετίνη
- GLP-1 ανάλογα
- Εξενατίδη
- Λιραγλουτίδη
- Μεταγευματική λιπαιμία
- Τριγλυκερίδια
- Σακχαρώδης διαβήτης τύπου 2
- Γαστρική κένωση
- Ταχυφυλαξία
- Incretin hormone
- GLP-1 analogues
- Exenatide
- liraglutide
- Postprandial lipaemia
- Triglycerides
- Type 2 diabetes mellitus
- Gastric emptying
- Tachyphylaxis
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42434